EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)Open Access · CC BY 4.0

A Novel Y-Shaped Pegylated Recombinant Human Growth Hormone for Children With Growth Hormone Deficiency

Yan Liang iD, Haiyan Wei, Fan Yang, Hua Zhang, Linqi Chen, Hui Yao, Xiaoming Luo, Xinran Cheng, Yu Yang, Qun Lian, Hongwei Du, Tang Li und 17 weitere

The Journal of Clinical Endocrinology & Metabolism · 15.07.2025 · 110 (8) · e2605-e2613

DOI: 10.1210/clinem/dgae816 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 28.11.2024. Verfasst von Yan Liang und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Hauptthemen laut MEDLINE: Dwarfism, Pituitary, Growth Disorders, Human Growth Hormone, Polyethylene Glycols. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Xiamen Amoytop Biotech Co, Ltd, Fourteenth Five-Year Plan, National Key Research and Development Projects.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Pegpesen is a novel Y-shape pegylated recombinant human growth hormone (rhGH) for once-weekly treatment of children with growth hormone deficiency (GHD).

Objective

This work aimed to evaluate the efficacy and safety of Pegpesen in children with GHD vs daily rhGH.

Methods

A multicenter, randomized, controlled phase 3 clinical trial was conducted at 23 centers in China with a duration of 52 weeks’ treatment. There were 391 pediatric participants diagnosed with GHD. Participants were randomly assigned 2:1 to a weekly Pegpesen group (140 μg/kg/week) or a daily rhGH group (245 μg/kg/week) for 52 weeks. The primary end point was the growth velocity (GV) at 52 weeks, and the secondary end points mainly involved changes from baseline in height SD scores for chronological age and bone age (ΔHt SDS CA and ΔHt SDS BA).

Results

At 52 weeks, the least squares mean (LS means) of GV was 9.910 cm/year in the Pegpesen group and 10.037 cm/year in the daily rhGH group. The LS means difference between groups was −0.127 (95% CI, −0.4868 to 0.2332), confirming that weekly Pegpesen is noninferior to daily rhGH. The LS means of ΔHt SDS CA, ΔHt SDS BA, were similar across both groups (all P > .05). Safety profiles and adherence were comparable.

Conclusion

Pegpesen was noninferior to daily rhGH, with similar safety, lower dosage requirements, thus presenting a new therapeutic option for children with GHD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dwarfism, PituitaryGrowth DisordersHuman Growth HormonePolyethylene GlycolsAdolescentChildChild, PreschoolFemaleHumansMaleBody HeightChinaRecombinant ProteinsTreatment Outcome

Stichwörter der Autor:innen

Y-shape pegylated rhGHgrowth hormonegrowth hormone deficiencylong-acting growth hormonepediatric

Substanzen

Human Growth HormonePolyethylene GlycolsRecombinant Proteins

Autor:innen und Institutionen

  • Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
  • Department of Endocrinology, Genetics and Metabolism, Children's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou 450018, China.
  • Department of Pediatrics, Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu 610066…
  • Department of Pediatrics, Sanya Central Hospital, Sanya 572000, China.
  • Department of Endocrinology, Metabolism and Genetic Disorders, Children's Hospital of Soochow University, Suzhou 215003, China.
  • Department of Genetic Metabolism and Endocrinology, Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430015, China.

ORCID-Profile: Yan Liang, Zhe Su, Xiaoping Luo

Förderung

  • Xiamen Amoytop Biotech Co, Ltd
  • Fourteenth Five-Year Plan
  • National Key Research and Development Projects

Zitieren

APA

Liang, Y., Wei, H., Yang, F., Zhang, H., Chen, L., Yao, H., Luo, X., Cheng, X., Yang, Y., Lian, Q., Du, H., Li, T., Li, P., Zhang, G., Song, F., Liang, L., Liu, D., Zhu, S., Gong, H., …, & Luo, X. (2025). A Novel Y-Shaped Pegylated Recombinant Human Growth Hormone for Children With Growth Hormone Deficiency. The Journal of Clinical Endocrinology & Metabolism, 110(8), e2605-e2613. https://doi.org/10.1210/clinem/dgae816

Vancouver

Liang Y, Wei H, Yang F, Zhang H, Chen L, Yao H, et al. A Novel Y-Shaped Pegylated Recombinant Human Growth Hormone for Children With Growth Hormone Deficiency. The Journal of Clinical Endocrinology & Metabolism. 2025;110(8):e2605-e2613. doi:10.1210/clinem/dgae816

BibTeX
@article{Liang2025,
  author = {Liang, Yan and Wei, Haiyan and Yang, Fan and Zhang, Hua and Chen, Linqi and Yao, Hui and Luo, Xiaoming and Cheng, Xinran and Yang, Yu and Lian, Qun and Du, Hongwei and Li, Tang and Li, Pin and Zhang, Gaixiu and Song, Fuying and Liang, Liyang and Liu, Deyun and Zhu, Shunye and Gong, Haihong and Gong, Chunxiu and Cheng, Xiangao and Xu, Zhuangjian and Ma, Yaping and Su, Zhe and Zhou, Weidong and He, Ruoyi and Yin, Yalin and Sun, Li and Luo, Xiaoping},
  title = {A Novel Y-Shaped Pegylated Recombinant Human Growth Hormone for Children With Growth Hormone Deficiency},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  volume = {110},
  number = {8},
  pages = {e2605--e2613},
  doi = {10.1210/clinem/dgae816}
}
Kostenlos starten →